(rac)-Modipafant-d4

• 常用名: (rac)-Modipafant-d4
• 英文名: (rac)-Modipafant-d4
• CAS号: 1794707-03-1
• 分子量: 609.11
• 密度: N/A
• 沸点: N/A
• 分子式: C₃₄H₂₅D₄ClN₆O₃
• 熔点: N/A
• 闪点: N/A

(rac)-Modipafant-d4用途

(rac)-Modipafant-d4(UK-74505-d4)是氘标记的(rac)-Modipafant。(Rac)-Modipafant(UK-74505)是一种口服活性、选择性、长效的不可逆血小板活化因子受体(PAFR)拮抗剂。(Rac)-莫迪帕芬预防登革热感染[1][2][3]。

(rac)-Modipafant-d4名称

• 英文名: (rac)-Modipafant-d4

(rac)-Modipafant-d4生物活性

• 描述: (rac)-Modipafant-d4(UK-74505-d4)是氘标记的(rac)-Modipafant。(Rac)-Modipafant(UK-74505)是一种口服活性、选择性、长效的不可逆血小板活化因子受体(PAFR)拮抗剂。(Rac)-莫迪帕芬预防登革热感染[1][2][3]。
• 相关类别:
  研究领域 >> 感染
  信号通路 >> 其他 >> 其他
  研究领域 >> 炎症/免疫
• 体外研究: 氢、碳和其他元素的稳定重同位素已被纳入药物分子,主要作为药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注[1]。
• 参考文献:

  [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

  [2]. O'Connor BJ, et al. Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans. Am J Respir Crit Care Med. 1994;150(1):35-40.

  [3]. Alabaster VA, et al. UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. Agents Actions Suppl. 1991;34:221-227.

  [4]. Parry MJ, Alabaster VA, et al. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity. J Lipid Mediat Cell Signal. 1994;10(3):251-268.

  [5]. Souza DG, et al. Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection. Proc Natl Acad Sci U S A. 2009;106(33):14138-14143.

  [6]. Guerrero AT, et al. The role of PAF/PAFR signaling in zymosan-induced articular inflammatory hyperalgesia [published correction appears in Naunyn Schmiedebergs Arch Pharmacol. 2013 Apr;386(4):351. Zaperlon, Ana C [corrected to Zarpelon, Ana C]]. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(1):51-59.

(rac)-Modipafant-d4物理化学性质

• 分子式: C₃₄H₂₅D₄ClN₆O₃
• 分子量: 609.11